Physician profile
Scott A Liberty
NPI 1053641886
$3,032.02
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,197 · 2022: $1,749 · 2023: $69.29 · 2024: $17.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $86.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $86.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $556.10 | 2021-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $531.56 | 2021-2024 | Trelegy Ellipta |
| Abbvie INC. | $516.36 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $356.64 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $211.69 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $211.07 | 2021-2022 | |
| Abbott Laboratories | $176.29 | 2021-2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $139.26 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $117.38 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $44.99 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.88 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $32.38 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.24 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.62 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.26 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14.74 | 2023 | |
| Astellas Pharma US INC | $14.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Liberty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.